<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phgenomics</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакогенетика и фармакогеномика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacogenetics and Pharmacogenomics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2588-0527</issn><issn pub-type="epub">2686-8849</issn><publisher><publisher-name>LLC "Izdatelstvo OKI"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24411/2588-0527-2018-10022</article-id><article-id custom-type="elpub" pub-id-type="custom">phgenomics-102</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАКОГЕНЕТИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACOGENETICS STUDY</subject></subj-group></article-categories><title-group><article-title>Оценка клиренса ванкомицина у больных хирургического профиля с нарушениями функции почек</article-title><trans-title-group xml:lang="en"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хайтович</surname><given-names>Е. Д.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Морозова</surname><given-names>Т. Е.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ФГАОУ ВО Первый МГМУ имени И.М. Сеченова Минздрава России (Сеченовский Университет)</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>22</day><month>03</month><year>2020</year></pub-date><volume>0</volume><issue>2</issue><fpage>44</fpage><lpage>44</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Хайтович Е.Д., Морозова Т.Е., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Хайтович Е.Д., Морозова Т.Е.</copyright-holder><copyright-holder xml:lang="en">Хайтович Е.Д., Морозова Т.Е.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/102">https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/102</self-uri><abstract><p>Проведено сравнение результатов расчёта клиренса ванкомицина различными методами у больных хирургического профиля с нарушениями функции почек. Результаты исследования свидетельствуют о необоснованности применения различных методик расчёта и прогнозирования значений Clvan на основании расчётных значений клиренса креатинина в группе пациентов с нарушением функции почек.</p></abstract><kwd-group xml:lang="ru"><kwd>клиренс</kwd><kwd>ванкомицин</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925–942.</mixed-citation><mixed-citation xml:lang="en">Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925–942.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988;32:848–852.</mixed-citation><mixed-citation xml:lang="en">Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988;32:848–852.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother. 2009;53(5):1863–1867.</mixed-citation><mixed-citation xml:lang="en">Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother. 2009;53(5):1863–1867.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">DeRyke CA, Alexander DP. Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentration-time curve/minimum inhibitory concentration. Hosp Pharm. 2009;44(9):751–756.</mixed-citation><mixed-citation xml:lang="en">DeRyke CA, Alexander DP. Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentration-time curve/minimum inhibitory concentration. Hosp Pharm. 2009;44(9):751–756.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. DOI: 10.1159/000180580</mixed-citation><mixed-citation xml:lang="en">Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. DOI: 10.1159/000180580</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
